GovChime
Notice ID: 1c43ff3054a948a39df811de8826d46dPresolicitation

One Lambda/ Various reagents.

Archived on May 26, 2020. Original response deadline: . Full description on SAM.gov.

Overview

Response deadline
10:30 AM UTC−04:00
Posted
May 1, 2020
Notice type
Presolicitation
NAICS
325413: In-Vitro Diagnostic Substance Manufacturing
Agency
Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH

Notice details

Office
NATIONAL INSTITUTES OF HEALTH - CC
Place of performance
Bethesda, MD, 20892
Last updated
Dec 4, 2025

Identifiers

Solicitation number
20-007294
Notice ID
1c43ff3054a948a39df811de8826d46d

Description

INTRODUCTION THIS IS A PRE-SOLICITATION NON-COMPETITIVE (NOTICE OF INTENT) SYNOPSIS TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). The National Institutes of Health (NIH), Clinical Center (CC), Office of Purchasing and Contracts (OPC) on behalf of the Center for Cellular Engineering (CCE), Clinical Center (CC) at the National Institutes of Health (NIH) intends to negotiate and award a contract without providing for full and open competition (Including brand-name) to: One Lambda Inc. 21001 KITTRIDGE ST Canoga Park, CA, 91303-2801 UNITED STATES NORTH AMERICAN INDUSTRY CLASSIFICATION SYSTEM (NAICS) CODE The intended procurement is classified under NAICS code 325413 with a Size Standard 1250 employees. REGULATORY AUTHORITY The resultant contract will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 2020-4, January 15, 2020. STATUTORY AUTHORITY This acquisition is being conducted using policies unique to FAR Part 13.5 Simplified Acquisition for Certain Commercial Items and specifically FAR 13.501(a) Special Documentation Requirements, Sole source (including brand name) acquisitions where acquisitions conducted under Simplified Acquisition procedures are exempt from the requirements of FAR 6, but still require a justification using the format of FAR 6.302-2. The total dollar value of the acquisition shall not exceed $7,000,000.00. GENERAL INFORMATION 1. Title: One Lambda /Various reagents. 2. Background Information: The function of the Human Leukocyte Antigen Laboratory (HLA) of the Department of Transfusion Medicine, CC is to (1) provide clinical diagnostic laboratory testing for patients in the Clinical Center to facilitate possible transplant or enrollment into an appropriate protocol for the patients particular condition; (2) to conduct clinical consultations for NIH Clinical Center physicians in the management of patient care in regards to potential transplant scenarios; (3) to maintain accreditation through various accrediting agencies in order to provide quality results (4) to conduct research in the development of new diagnostic laboratory tests (5) to facilitate the support and development of protocols which involve HLA testing and the implications for patient care. 3. Purpose or Objective: The National Institute of Health, Clinical Center (CC) intends to award a one year fixed price Indefinite Delivery Indefinite Quantity (IDIQ) contract to One Lambda, Inc., Canoga Park, California 91303-2801, DUNS# 118289289 for the acquisition of LabType SSO/PRA/Class Typing Kits. The proposed vendor, One Lambda, Inc., is the only manufacturer of the various LabType SSO/PRA/Class Typing kits. These kits are used for routine Human Leukocyte Antigen (HLA) testing and HLA antibody screening utilizing the Luminex methodology as 510K FDA cleared products. While other platforms may be available, these platforms have not been found to have all the various types of kits needed for HLA testing. Any change to another platform would require validation to ensure the kits and testing work as stated, which would take months to perform. It is imperative due to the diagnostic nature of the testing, that diagnostic test kits are not changed without proper testing. These items need to be awarded before June 10, 2020 to ensure no disruptions in HLA testing. In addition, One Lambda is the only company which provides a LabType typing reagent for high resolution Class II DRB1 Loci testing. This level of resolution is necessary to provide information to several primary investigators at NIH who are involved with numerous protocols, including transplantation protocols. 4. Period of Performance: Base plus 4 option years estimate beginning in June 2020. CONTRACTOR REQUIREMENTS (SCOPE OF WORK) 1. Requirements- The following reagents will be purchased with the breakdown of estimated annual price. Either reagents listed or those of an equivalent upgrade will be included in this contract. Reagent Name Catalog # Estimated Quantity LABType A Locus RSSO1A 35 LABType B Locus RSSO1B 35 LABType C Locus RSSO1C 35 LABType DRB1 Locus RSSO2B1 30 LABType DQA/B1 Loci RSSO2Q 30 LABType DRB345 Loci RSS02345 30 LABScreen PRA Class I LS1PRA 26 LABScreen PRA Class II LS2PRA 24 LABScreen Single Antigen Class I LS1A04 14 LABScreen Single Antigen Class II LS2A04 6 Secore A 5300025 8 Secore C 5320025 2 Secore B 5311025D 2 Secore DRB1 A15571 20 Secore DQB1 5341025D 6 Secore DPB1 5351025 6 DNA Wipe Test 789991 5 SAPE LT-SAPE 18 ADSORB ADSORB 7 LABScreen Negative Control LS-NC 10 PE Congugated Goat Anti-Human IgG LS-AB2 3 Lambda Antigen Tray Class I and II LAT-1240 2 KIR SSO Genotyping Test RSSOKIR 4 KIR Genotyping SSP Kit 54410D 3 FREIGHT 2. Deliverables: Reagents will be delivered according to need within 3 days of order placement. Volumes indicated on the quote are for estimated use ONLY there is no requirement to purchase a predetermined number of any kit/reagent. CLOSING STATEMENT This synopsis is not a request for competitive proposals. However, interested parties may identify their interest and capability to respond to this notice. Responses to this notice shall contain sufficient information to establish the interested parties' bona-fide capabilities for fulfilling the requirement and include a technical proposal, a cost-price proposal, the period of performance, the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement. All responses must be received by May 11, 2020, 10:30 AM Eastern time and must reference pre-solicitation number 20-007294. Responses may be submitted electronically to Mrs. Grace Wong-Darko, Contracting Specialist at grace.wong-darko@nih.gov. Fax responses will not be accepted. "All responsible sources may submit a capability statement, proposal, or quotation, which shall be considered by the agency." Small businesses are encouraged to respond to this notice if they are capable to meet the needs of this requirement. Written responses to this notice shall contain sufficient documentation to establish bonafide capability to fulfill the requirement.

Full description on SAM.gov

Award Overview

No prior contract identified

No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.

Contacts

Documents

No documents available.

Lifecycle

Solicitation:20-007294
  1. Pre-Solicitation

Formal solicitation typically follows within 30–60 days. (estimate)

  1. Pre-SolicitationCurrentMay 1, 2020

    One Lambda/ Various reagents.

    Notice 1c43ff3054a948a39df811de8826d46d on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline
Please see attached Combined Synopsis/Solicitation. See attached estimated quantities and Questions and Answers.
-Combined Synopsis11/18/2026
(i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in FAR Subpart 12.6, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested, and a separate written solicitation will not be issued. (ii) The solicitation number is 75N98027Q00027. This solicitation is issued as a Notice of Intent (NOI) for a non-competitive combined synopsis/solicitation to award a contract or purchase order without providing for full and open competition (including brand-name, if applicable). This acquisition is conducted under the authority of FAR 12.603, Streamlined Solicitation for Commercial Products or Commercial Services, and is not expected to exceed the simplified acquisition threshold. Additional authority includes 41 U.S.C. 1901 and FAR 6.302-3(a)(2)(ii). The National Institutes of Health (NIH), Office of the Director, Office of Acquisitions, intends to negotiate and award a firm-fixed-price purchase order on a non-competitive basis to Integrated DNA Technologies, Inc. (IDT), 1710 Commercial Park, Coralville, IA 52241, for custom-designed ArcherDX VariantPlex Next-Generation Sequencing (NGS) target-enrichment library preparation kits. Integrated DNA Technologies, Inc. is the sole owner, manufacturer, and distributor of the proprietary ArcherDX VariantPlex Anchored Multiplex PCR (AMP) chemistry, which has been utilized by the NHLBI Hematology Branch since 2019 to perform error-correcting sequencing (ECS) and is required to maintain scientific continuity, prevent technical batch effects across longitudinal patient cohorts, and ensure compatibility with the laboratory¿s established Archer Analysis bioinformatics pipeline. All responsible sources may submit a capability statement, proposal, or quotation, which shall be considered by the agency. (iii) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2026-01, effective 03/13/2026. (iv) The associated NAICS code is 325413 (In-Vitro Diagnostic Substance Manufacturing) and the small business size standard is 1,250 employees. This requirement is not set aside for small business.
-Combined Synopsis11/05/2026
See attached Sources Sought Notice.
-Market Research10/28/2026
-Sole Source / J&AOpen
See Soliciation Amendments 0001, 0002, and 0003. USAISR's Combat Casualty Care Research Team 1 (CRT-1) requires resupply of its Blood Donor Room on a reoccurring basis in order to satisfy research requirements for blood collection. USAISR currently has three Terumo Trima Accel Blood Collection Systems in operation. These units support numerous research protocols. Various collection sets are used to collect a variety of blood products from donors. The Trima instrument is FDA-approved, but only with the use of original manufacturer-supplied consumable products. These consumables are specific to the instrument and there are no generic substitute products available in the marketplace. Please note - This is a 100% set-aside for Service-Disabled Veteran-Owned Small Businesses. See attached complete solicitation for all requirement details and instructions to offerors.
-Solicitation11/20/2026

Additional Details

Solicitation Number

20-007294

Archive Date

May 26, 2020

Office Address

BETHESDA, MD, 20892